Existing evidence suggests that TLR3 ligands can be used as anticancer agents and that a combination of CD40 and TLR agonists may synergistically act as immunostimulants by suppression of tumor growth in mice (Stone et al., 2009). Here, CD40 is linked to neoplasm.